SCHEMBL4676263

SCHEMBL4676263

O=C(Cc1ccc(Cc2ccncc2)[nH]1)C(=O)c1nc[nH]n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
MAPT P10636 3/20 0.35
CYP3A4 P08684 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
LMNA P02545 3/20 0.34
CYP19A1 P11511 1/20 0.33
POLB P06746 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
HDAC1 Q13547 2/20 0.31
HDAC6 Q9UBN7 1/20 0.31
ALDH1A1 P00352 2/20 0.31
TSHR P16473 1/20 0.31
CYP17A1 P05093 1/20 0.31
HDAC3 O15379 1/20 0.31
HPGD P15428 1/20 0.31
CPT1A P50416 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4679269 0.89 HCAR2 (0.39) HRH3LMNAHPGDKDM5AKDM5B
SCHEMBL4679207 0.86 LMNA (0.36) SMN1; SMN2LMNA
SCHEMBL4672268 0.86 HRH3 (0.37) HRH3CYP3A4ALDH1A1TSHR
SCHEMBL4671320 0.86 BRS3 (0.34) MAPTSMN1; SMN2LMNAALDH1A1KDM5A
SCHEMBL4673640 0.85 KDM5A (0.42) SMN1; SMN2LMNAPOLBALDH1A1KDM5A
SCHEMBL4672702 0.84 KMT2A (0.41) HRH3MAPTSMN1; SMN2LMNAPOLB
SCHEMBL4670917 0.82 HRH4 (0.37) HRH4HRH3MAPTCYP3A4SMN1; SMN2
SCHEMBL4674197 0.82 HRH4 (0.34) HRH4HRH3MAPTCYP3A4SMN1; SMN2
SCHEMBL4674898 0.81 HRH3 (0.40) HRH4HRH3MAPTSMN1; SMN2LMNA
SCHEMBL4679657 0.80 HCAR2 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 HRH4 479/4885HRH3 471/4885MAPT 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.